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An orphan drug signifies an official designation in the
European drug supervision. A medicinal product can be
designated as an orphan medicinal product if it is in-
tended for a condition affecting not more than five in
ten thousand people in the EU. The condition must be
life-threatening or chronically debilitating. If the condi-
tion is less severe, it is possible to obtain orphan drug
status on the basis that the rare use of the product
would not cover its development costs.
Another condition for the granting of the status is
that the drug is either the only drug used for the rare
condition in question or that the product is expected to
provide significant improvement compared with the
therapies in use at present.
Applications for orphan medicinal product designa-
tions are submitted to the European Medicines Agency
(EMEA), where the documentation supplied concerning
the product  will be evaluated by the Committee for Or-
phan Medicinal Products (COMP).
Since its establishment in April 2000 the Committee
has processed about 350 applications. Orphan drug sta-
tus has been granted to over 200 products, 15 of which
had obtained marketing authorisation by June 2004. Of
these, bosentan (for pulmonary arterial hypertension),
imatinib (for the treatment of certain chronic forms of
myeloid leukaemia and gastro-intestinal stromal tu-
mours, GIST) and pegvisomant (for acromegaly) are for
sale in Finland.
A developer of a new drug may apply for orphan
drug status for his product at any stage of the develop-
ment, and consequently, a designation once obtained
does not guarantee a marketing authorisation. A desig-
nation is often applied for as early as at the stage of pre-
clinical studies.
If marketing authorisation is granted for an orphan
drug, the marketing authorisation holder has 10-year
exclusive sales rights in the therapeutic indication in
question, unless superior treatment alternatives can be
offered by competitors.
Generic competitors in the area of therapeutic indi-
cations of the orphan drug are prohibited for 10 years
even when the active substances of several orphan drugs
have passed their patent protection period. The status
has in that case been obtained on the grounds of a spe-
cial property affecting the route of administration, dura-
tion of effect, etc., which has been used for a familiar
medicinal substance to render it effective in the treat-
ment of a rare condition.
The EMEA is to start publishing data about orphan
drug marketing applications relating to their active sub-
stances, the indications on the grounds of which the au-
thorisation is applied for, and concerning the applicants
for the marketing authorisations. This will allow anyone
else involved to become familiar as early as possible
with the fact that the medical treatment for the rare
condition in question may become a special area for
which competition restrictions are going to apply for a
fixed term.
Orphan drug status is a valuable designation for the
developer of a new drug. It serves to demonstrate the
fact that independent experts have evaluated the devel-
opment project and found it to be good. The status will
in particular strengthen the confidence in the project by
both the drug developers and those investing their mon-
ey in the development work. Scientific advice and sup-
port to orphan drug developers in marketing authorisa-
tion issues will also be available from the authorities.
Veijo Saano
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There are three main types of uri-
nary incontinence. In stress inconti-
nence dribbling occurs immediately
in association with straining, cough-
ing or lifting. About 60% of cases of
urinary incontinence in women are
of this type, with peak prevalence
between the ages of 50 and 55. In
urge incontinence, a strong sense of
urgency to void is experienced be-
fore the involuntary passage of
urine. Mixed urinary incontinence is
the involuntary passage of urine
caused by a combination of both
stress and urgency. Overactive blad-
der is a more recent definition which
is associated with a sense of urgency,
more frequent need to void, but it is
not necessarily associated with
awareness of involuntary loss of
urine.
What is the cause?
For the maintaining of normal uri-
nary continence the co-operation of
the brain, the peripheral nerves, the
connective tissues, the muscles and
the hormones is necessary. Disturbed
working of any of these functions
may therefore impair the ability to
maintain continence. In stress uri-
nary incontinence, weakness of the
urethra and/or the surrounding sup-
portive structures is present. In urge
incontinence, excessive activity of
the bladder wall muscle is causing
the symptoms. It is not always pos-
sible to find an obvious reason for
the poor capacity of the bladder to
stretch, and it is consequently com-
mon to speak of idiopathic overac-
tivity of the bladder wall.
Risk factors
Obesity is an independent risk factor
for urinary and faecal incontinence.
The amount of excess weight is re-
lated to the quantity of escaping
urine. Chronic cough and obstruc-
tive pulmonary diseases may impair
the supportive structures of the ure-
thra and result in more severe uri-
nary incontinence. Neurological dis-
eases may result in an overactive
bladder by disturbing the normal
pontine micturition centre. Such dis-
eases include cerebral infarction,
Alzheimer’s disease, Parkinson’s dis-
ease, multiple sclerosis and cerebral
palsy. Other concomitantly occur-
ring conditions associated with uri-
nary incontinence include constipa-
tion, diabetes, depression and back
back complaints.
There is contradictory evidence
of the effect of hysterectomy on uri-
nary incontinence. The age at which
hysterectomy was carried out is of
consequence to the symptoms of uri-
nary incontinence. The failure of
other supportive structures of the
pelvic floor may be associated with
urinary incontinence, or urinary in-
continence may occur without other
symptoms of loss of tone. Problems
of micturition may occur following
gynaecological reconstructive
surgery. Poor contraction of the
pelvic floor muscles is a risk factor
for urinary incontinence.
Pregnancy, childbirth and 
urinary incontinence
Both pregnancy and childbirth
weaken the supportive structures of
the pelvic floor and may conse-
quently expose the patient to uri-
nary incontinence later in life. Invol-
untary passage of urine has been re-
ported by as many as 50% of preg-
nant women. Fortunately, post-de-
livery urinary incontinence remains
a permanent complaint in only
3–11% of women who have given
birth. The pudendal nerve lying at
the bottom of the pelvic floor may
become temporarily or permanently
damaged during delivery. The nerve
recovers by itself within two
months, so the follow-up examina-
tion at a maternity health centre
should include an assessment of the
pelvic floor function. Risk factors
for urinary incontinence include the
maternal weight, the child’s weight,
the duration of the expulsive stage
of labour, operatively assisted deliv-
ery and rupture of the anal sphinc-
ter. The first childbirth appears to be
the most significant one. A Norwe-
gian demographic study (involving
15,307 women) found that both
women who had undergone caesare-
an section and women who had had




Involuntary passage of urine is a common health problem in women which is associated with im-
pairment of the quality of life. The incidence of the condition is age-related inasmuch as it occurs
in 12–42% of young women and in 17–55% of older women. Urinary incontinence occurs in all
human races, all social classes and also in men, even though the incidence in men does not increase
until after the age of 60.
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spontaneous delivery had more fre-
quent stress and mixed urinary in-
continence than women of corre-
sponding age who had not given
birth. Absence of childbirth in a
woman’s history does not, however,
give full protection against urinary
incontinence. Emerging risk factors
for urinary continence found in a
study of women who had not given
birth included high body weight,
urinary tract inflammation, depres-
sion and hysterectomy.
Ageing and urinary incontinence
Structural defects of nerve, muscle
and supportive structures and im-
paired functions associated with
ageing all present a risk for urinary
incontinence. The incidences of
stress and mixed urinary inconti-
nence increase with age. Despite
age-related reduced muscular func-
tion and hormonal changes in
women, demographic studies do not
show increased incidence of stress
urinary incontinence. When examin-
ing the causes of urinary inconti-
nence in the elderly one should bear
in mind any temporary causes that
may exist: delirium, inflammation,
atrophy/inflammation of the vaginal
mucosa, medicinal substances, psy-
chiatric illnesses, increased secretion
of urine (heart failure, hypergly-
caemia), restricted mobility and dif-
ficulties in emptying the bowel.
What examinations are 
necessary?
Important details are provided by
the patient’s own account of how
and when the urinary incontinence
started and when it most typically
occurs. Appropriate questionnaires
for this purpose are available from
pharmaceutical manufacturers. It is
often difficult for both the patient
and the doctor to get a picture of
the true nature of the complaint. In
that case, the patient should be
asked to fill in a bladder diary for a
few days. Women should undergo a
gynaecological examination and
men should have their prostates pal-
pated. A clean urinary sample is
part of the basic examination.
When the frequency of involun-
tary passage of urine is less than five
times per week, a mild form of the
condition is present. More than ten
involuntary passings of urine per
week is an indication of a severe
condition.
Treatment in out-patient care
Conservative, i.e. non-surgical, treat-
ment can be started when a basic re-
view of the patient has been carried
out and a picture of the type of the
urinary incontinence established.
The conservative treatment consists
of: guided pelvic floor muscle train-
ing, training of the bladder, electrical
stimulation, medical treatment,
changes of lifestyle, aids and appli-
ances, and incontinence protection.
If the treatment response is good
and there is no uncertainty as to the
diagnosis, the treatment is continued
in out-patient care. For the sake of
treatment response, it is important
that both the professional offering
the therapy and the patient are com-
mitted to the therapy.
Guided pelvic floor muscle 
training
The pelvic floor muscles assist in
closing the urethra provided the
muscles are intact and attached to
the surrounding tissues. After child-
birth and with age, the function of
these muscles may be insufficient,
and training under the guidance of a
physiotherapist may be appropriate.
Training the pelvic floor muscles is
appropriate treatment of mild or
moderate stress or mixed urinary in-
continence.
The training should follow the
general principles of muscular exer-
cises. In several studies two in three
women with stress incontinence
have been reported to have benefited
from muscular training, even though
full urinary control has not been
gained by all women (1). With
biofeedback devices a physiothera-
pist can help the patient to achieve
the objective of muscular training.
With the aid of a biofeedback device
the patient is able to listen to the
training instructions at home by us-
ing headphones while the device is
registering the performance.
Vaginal balls can also be used to
promote muscular training. It
should be borne in mind, however,
that results can only be achieved by
active muscular work. In general,
the method of using vaginal balls
has not been found superior to using
pelvic floor muscle training alone.
Electric stimulation
Therapy consisting of electric stimu-
lation has been used in muscular
training for the treatment of stress
urinary incontinence to relax the
bladder contraction function in urge
urinary incontinence. Electric stimu-
lation can be used to supplement
pelvic floor muscle training and oth-
er treatment; but, in stress urinary
incontinence it will, however, not
convey any supplementary effect to
the pelvic floor muscle training.
Training of the urinary bladder
It is typical of patients suffering
from urge urinary incontinence or
overactive bladder to micturate fre-
quently, even as often as 20 times a
day. Increasingly frequent visits to
the toilet will reduce the storage ca-
pacity of the bladder. The aim of
bladder training is gradually to de-
crease the frequency of micturition
and thereby increase the capacity of
the bladder. The patient aims at
gradually tolerating the sensation of
the urge to micturate. Keeping a di-
ary during the training is recom-
mended. Normally, the micturition
interval is 3–4 hours in daytime, and
a person of working age goes to the
toilet once a night at the most.
In some patients it may also be
necessary to review the amount and
timing of liquid consumed and the
schedule of administration of some
agents, such as diuretics, with an ef-
fect on the urinary secretion.
Medical treatment
Anticholinergics are superior to
placebos in the treatment of the
overactive bladder (2). They de-
crease the involuntary contractions
of the bladder wall muscles. The an-
ticholinergics in use in Finland at
present are oxybutynin, tolterodine
and trospium chloride. The most
common adverse effects of anti-
cholinergics are dryness of the
mouth, constipation and difficulty
with close vision. Once daily admin-
istration of a slow-release formula
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drug would appear to have fewer
adverse effects. Despite the theory
that anticholinergics would impair
the memory performance, they are
also used in dementia patients when
urinary incontinence is a consider-
able disadvantage.
New medicinal substances for
the treatment of the overactive blad-
der are under study, because its? ad-
verse effects can cause a number of
patients to stop using a drug.
Acetylcholine is secreted via the
muscarinic receptors. The largest
quantity of M2 receptors is to be
found in the urinary bladder, but it
is the M3 receptors that exert the
greatest effect on the detrusor mus-
cle contraction. Both darifenacin
and solifenacin have been found to
decrease the frequency of involun-
tary passages of urine. In a ran-
domised study (involving 1,077 pa-
tients), solifenacin 5 mg or 10 mg
administered once daily significantly
decreased the number of involuntary
passings of urine and the frequency
of needing to void it. As a conse-
quence of adverse reactions, 14%
and 21% of patients drop out of the
treatment (3). 
Dopamine, serotonin and norepi-
nephrine (noradrenalin) are nerve
transmitter agents which take part
in lower urinary tract regulation.
Duloxetine has a balanced double
effect: it inhibits the norepinephrine
and serotonin re-uptake. In clinical
studies done so far it has been found
to have a dose-dependent effect on
the reduction of frequency of invol-
untary passing of urine superior to
that of a placebo. Under trial condi-
tions duloxetine has been found to
increase the urethral contractor
muscle activity, and it is consequent-
ly expected to be of benefit in stress
urinary incontinence. Compared
with a placebo, the reduction in the
frequency of involuntary passing of
urine was statistically significant in a
study involving 458 women (54%
compared with 40%, p = 0.05). The
most common undesirable effect
with the use of duloxetine 40 mg
twice daily is nausea and feeling of
faintness. Seventeen per cent of the
patients withdrew from the medical
treatment due to adverse reactions
(4).
In postmenopausal women, oe-
strogen has not been found to de-
crease the quantity of urine involun-
tarily passed. Topical treatment of
mucosal membrane atrophy with oe-
strogen in post-menopausal women
is nevertheless recommended, be-
cause it objectively reduces the num-
ber of cases of urinary tract inflam-
mation and the experience of the pa-
tients is that it reduces the symp-
toms associated with the lower uri-
nary tracts.
When surgery?
Surgery is appropriate in patients
with stress or mixed urinary inconti-
nence and in whom conservative
treatment has not produced an ade-
quate response and the restriction
imposed by involuntary passage of
urine is significant to the daily life of
the patient. National criteria for
surgery in urinary incontinence are
expected to be published later this
year. The surgical techniques have
during the last decade undergone a
radical change towards more patient
friendly and safer procedures. Using
correctly chosen criteria of surgery,
nine out of ten women will become
dry following day case surgery.
Modern surgery aims at preserving
the structure of the pelvic floor in-
tact by supporting the urethra with
a synthetic mesh. The most exten-
sively studied new surgical method
is the TVT (tensionfree vaginal tape)
procedure (5), which will soon be
accompanied by the introduction of
TOT, transobturator tape technique)
and TVT-O transobturator TVT
(TVT-O, “inside-to-out” suburethral
sling for the treatment of stress uri-
nary incontinence (SUI)) procedures.
Initially, the results of these proce-
dures are equal to those with TVT,
but the leakage and the problems as-
sociated with the urinary bladder
penetration are less significant. 
Several different types of treat-
ment methods have been available
for urinary incontinence without
thorough preceding investigations.
Examples of these include the ure-
thral cap, the type of vaginal sup-
port which elevates the urethra,
vaginal tampons and various peri-
urethral bulking injections. Practice
has shown, however, that only good
clinical therapeutic examinations
can guarantee efficacy. Treatment of
urinary incontinence is rewarding
since both the conservative and the
surgical treatments are proven to
improve the patient’s quality of life
and restore normal sexual activity
(6).
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More than 700,000 patients in Fin-
land will have found that one or
more of the refundable drugs they
have been receiving have been re-
placed with a less expensive generic
counterpart during the first year of
generic substitution. The drugs most
frequently replaced included antihis-
tamines, antidepressants and lipid-
reducing agents. Two-thirds of the
cost savings were nevertheless gener-
ated by the reductions in price of the
medicinal products appropriate for
substitution. The savings generated
by generic substitution inhibit in
particular the increase in drug costs
generated by the increased wide-
spread use of new, more costly
drugs. 
Generic substitution was intro-
duced in Finland in April 2003. This
new practice would require the
pharmacies to replace the medicinal
product prescribed by a doctor with
a less expensive generic counterpart
unless the doctor prohibits or the
buyer declines the replacement. The
National Agency for Medicines de-
cides whether a generic counterpart
can be substituted for another drug,
and the Agency also maintains a list
of approved substitutable drugs. 
Generic substitution is guided by
the so-called price corridor. Pre-
scribed products are replaced with
the cheapest or close to the cheapest
interchangeable generic or parallel
import products. The lowest limit of
a price corridor is the lowest price
of the substitutable products. The
upper limit is achieved by adding
EUR 2 to the lowest price, if the
least expensive product costs less
than EUR 40; or EUR 3, if the least
expensive product costs EUR 40 or
more. The a price corridor for dif-
ferent groups of substitutable drugs
is established quarterly following the
price notifications submitted by the
pharmaceutical companies.
Substitutable drug purchases
During the first year of generic sub-
stitution, from the beginning of
April 2003 until the end of March
2004, there were a total of 12.4 mil-
lion prescriptions for substitutable
drugs that were dispensed by phar-
macies and refunded from the health
insurance scheme. This is about
45% of all refunded prescriptions
during that time. A prescription in
this case is the same as one purchase
of a drug prescribed by a doctor.
The proportionate cost of substi-
tutable drugs among the total costs
of all refunded drugs during the year
was about 34%. In April 2003 the
proportion was 36% and in March
2004 it was less than 33%. The pro-
portion is diminished by the increas-
ing use of the more recent, more ex-
pensive drugs and by price reduc-
tions of the substitutable products.
The proportion may also increase,
of course, when more medicinal sub-
stances become substitutable as the
patent cover for the original prod-
ucts eventually runs out.
Drugs used for cardiovascular
diseases accounted for about 40%
of all prescriptions and costs of sub-
stitutable drugs (Table 1). Measured
by the number of prescriptions, the
biggest groups thereafter were anti-
infectives and drugs for the treat-
ment of the nervous system.
During the year, about one in
eight prescriptions containing a sub-
stitutable drug was at the pharmacy
replaced by a cheaper alternative.
The most common substitutions
made were of antihistamines (30%
of the prescriptions), antidepressants
(27%) and lipid-lowering agents
(23%). Substitutions were prohibit-
ed by the prescribers in only 0.4%
of the cases where substitutions
would have been possible, and
clients declined to accept a substitu-
tion in less than 11% of the cases.
The prescribed product in nearly
three out of four prescriptions was
already within the price corridor, in
which case there was no need to re-
place it.
Cost savings generated
Generic substitution aims at pro-
moting cost-effective medical treat-
ment. Savings are made both by ac-
tually concretely replacing products
with less expensive alternatives, and
by tougher price competition be-
tween pharmaceutical companies.
The total savings generated during
the first year of generic substitution
in Finland amounted to EUR 88.3
million, which is about 6% of the
total costs of drugs refunded from
the health insurance system during
the same period. The clients’ pro-
portion of the sum was EUR 39.2
million, and the savings in reim-
bursement costs payable by the So-
cial Insurance Institution totalled
EUR 49.1. The proportion for the
health insurance is higher than that
for the clients’ mainly because a
great number of drugs entitled to
special reimbursement fall into the
category of generic substitution.
Over half of the total savings were
generated by drugs used for cardio-
vascular diseases (Table 1). The pro-
portion of the total savings due to
substitution was about a third, EUR
28.8 million.
Over half of the savings created
by generic substitution came from
substituting lipid-lowering agents
and antidepressants (Table 2). The
cost saving for each substitution
was on average EUR 18.39. One
substitution involving the product
of citalopram saved almost EUR 56,
and that of the product simvastatin
about EUR 47. Other drug groups
where the substitutions created sig-
nificant savings were, for example,
beta blockers and ACE inhibitors.
The first year of generic substitution
Mareena Paldán Timo Klaukka
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The greatest cost savings, two
thirds of total costs, were created by
price reductions owing to tougher
price competition. These calcula-
tions do not, however, take into ac-
count any price changes or generic
substitutions in those substitutable
drugs which were not eligible for a
refund from the health insurance
system. Consequently, the actual
savings may well be even higher
than calculated.
Generic substitution reduced the
rate of the growth in the amount of
refunds during 2003. The cost of re-
funds from the health insurance sys-
tem, totalling EUR 917.5 million,
increased by less than 7% compared
with the previous year, whereas the
increase in 2002 was about 12%.
Price reductions of substitutable
drugs and raising the top limit of the
fixed co-payment from EUR 8.40 to
EUR 10 in the basic refund category
placed several less expensive drugs
outside the refunding system alto-
gether, e.g. some anti-inflammatory
analgesics and antibiotics. The num-
ber of patients receiving refunds did
in fact drop by about 2% in 2003
compared with the previous year.
The first year of generic substitu-
tion exceeded all expectations.
Clients have in the main been satis-
fied with the new procedure, and
considerable savings have been gen-
erated by the system. The prices of
individual substitutable products
were reduced by a maximum of over
80% in comparison with the prices
before generic substitution was in-
troduced. In future, the extent of
generated savings and the growth
rate of medicine costs will be depen-
dent, for example, on the number of
medicinal substances falling in the
category of suitability for generic
substitution, and the value of their
sales.
Table 1 .  Prescr ipt ions,  costs and savings for  substitutable products reimbursed by the national  health insur-
ance scheme in 1 .4.2003–31.3.2004
Prescriptions Costs Cost savings
In thousands     Share EUR 1 000             Share EUR 1 000          Share
A Alimentary tract and metabolism 648 5.2 % 28,660 5.9 % 3,650 4.1 %
B Blood and blood forming organs 45 0.4 % 1,553 0.3 % 16 0.0 %
C Cardiovascular system 4,604 37.1 % 197,790 41.0 % 46,941 53.2 %
D Dermatologicals 120 1.0 % 11,882 2.5 % 1,225 1.4 %
G Genito urinary system and sex hormones 512 4.1 % 28,984 6.0 % 2,376 2.7 %
H Systemic hormonal preparations 47 0.4 % 1,215 0.3 % 5 0.0 %
J  Antiinfectives for systemic use 2,013 16.2 % 39,715 8.2 % 7,377 8.4 %
L Antineoplastics and immunomodulating agents   144 1.2 % 23,880 5.0 % 304 0.3 %
M Musculo-skeletal system 1,508 12.2 % 34,760 7.2 % 4,443 5.0 %
N Nervous system 1,958 15.8 % 86,994 18.1 % 17,434 19.7 %
P Antiparasitic products. insecticides and repellants 20 0.2 % 268 0.1 % 23 0.0 %
R Respiratory system 680 5.5 % 23,914 5.0 % 3,846 4.4 %
S Sensory organs 92 0.7 % 2,214 0.5 % 660 0.7 %
All substitutable products 12,394 100.0 % 481,829            100.0 % 88,300           100.0 %
Source: Prescription Register at Kela
Table 2.  Drug groups and medicines (el igible for  reimbursement pay-
ments)  which generated the most  savings through generic  substitut ions
in 1 .4.2003–31.3.2004
Cost savings       Cost savings/exchange
EUR 1 000 Share Eur
C10 Serum lipid reducing agents 7,970 27.7 % 44.59
Simvastatin 7,613 26.5 % 47.16
Lovastatin 370 1.3 % 27.51
N06 Psychoanaleptics 7,905 27.5 % 43.98
Citalopram 7,312 25.4 % 55.78
Paroxetin 400 1.4 % 15.91
C07 Beta blocking agents 4,055 14.1 % 15.77
Bisoprolol 2,877 10.0 % 15.98
Atenolol 900 3.1 % 23.81
C09 Agents acting on the renin-angiotensin system 3,488 12.1 % 26.08
Enalapril 2,393 8.3 % 29.39
Enalapril and diuretics 624 2.2 % 23.15
Lisinopril 451 1.6 % 23.94
R06 Antihistamines for systemic use 1,242 4.3 % 12.31
Cetirizin 790 2.7 % 11.13
Loratadin 452 1.6 % 15.10
J01 Antibacterials for systemic use 1,107 3.8 % 8.88
Ciprofloxacin 878 3.1 %        22.45
J02 Antimycotics for systemic use 756 2.6 % 8.89
Fluconazole 756 2.6 % 8.89
G04 Urologicals 583 2.0 % 14.42
Finasteride 495 1.7 % 16.81
All substitutable products                                        28.759             100.0 %       18.39
Source: prescription Register at Kela
According to the Finnish Medicines
Act, the National Agency for Medi-
cines decides as necessary whether a
substance or a product should be
classified as a drug. The decision
may be requested, for example, by
the product manufacturer, the im-
porter, or the customs authorities.
Classification criteria
Products are classified in accordance
with their composition and the ther-
apeutic indications proposed. The
medicinal properties of the composi-
tion are referred to in the Agency’s
list of drugs where the substances
contained in Appendix 1 are medi-
cines, the herbal medicinal products
listed in Appendix 2 may be classi-
fied as medicines, and Appendix 3
lists the vitamin and mineral concen-
trations which, when exceeded, may
classify the product as a medicine.
The purpose of a product is med-
icinal if it is used according to the
specification of a drug in accordance
with Section 3 of the Medicines Act,
that is, for example, to cure, allevi-
ate or prevent a disease or its symp-
tom. A product or a substance used
either internally or externally to
identify a condition or the cause of a
disease, or to restore, correct or
modify the vital functions, in either
humans or animals.
Products are not automatically
classified as drugs despite the fact
that they contain the substances or
herbal medicinal products included
in the Agency’s list of drugs, or that
their vitamin and mineral concentra-
tions exceed the limits given in the
list. Products are classified as drugs
if they have a distinct medicinal pur-
pose although their composition
may not be medicinal (e.g. insulin
dilution solution). Even though the
purpose of the product may not be
medicinal, the product is a drug  if it
can produce physiological changes
or pharmacological reactions in the
body.
Statements relative to the vital
functions or the reduced risk of dis-
ease can be made on foodstuffs. 
Further information is provided in
the guide on health statements 
(Terveysväitteiden valvontaopas,
Finnish) published by the National
Food Agency (www.elintarvikeviras-
to.fi)
Classification and the EU
The national decisions on classifica-
tion in Finland are also influenced
by the Community legislation and
the established legal praxis of the
European Court of Justice. EU insti-
tutions have in their own statements
consistently endorsed the principle
of free competition and common in-
ternal markets aimed at reducing the
restrictions which inhibit competi-
tion. One such inhibition is, for ex-
ample, the maximum concentrations
of vitamins and minerals which,
when exceeded, would automatically
classify the product as a drug. Ac-
cording to a decision by the Euro-
pean Court of Justice in April, clas-
sifications cannot be designed fol-
lowing pre-set concentration limits;
each classification should instead be
established individually. National
variations are allowed; if a product
is not considered a drug in one
member state, it may nevertheless be
classified as a drug in another mem-
ber state on the grounds of its phar-
macological effects, for example.
However, for most vitamins and
minerals, scientific evaluations have
not been completed within the EU
with the aim of confirming the
“maximum values”, excess levels of
which would pose a health risk.
Maximum concentrations, which
would make a distinction between a
nutritional supplement and a drug,
have not been established either. The
most recent position paper on the is-
sue of concentrations was neverthe-
less published last spring. According
to the statement of judgement of the
European Court of Justice
(29.4.2004, case C-387/99), vitamin
preparations manufactured and sold
as nutritional supplements cannot
systematically be classified as drugs
when they contain three times the
recommended daily dose of vitamins
other than those of A and D; the
daily dose being that recommended




Once classified as a drug, the prod-
uct may not be placed on the market
as a foodstuff, but instead, a drug
marketing authorisation must be ap-
plied for. The commercial trader is
always responsible for the sale and
choice of appropriate channels of
marketing of its products. It is also
the trader’s responsibility to ensure
that a product classified as a drug is
withdrawn from the shelves of shops
selling foodstuffs. The supervisory
authorities may interfere with the il-
legal sale of the product.
Information on classification is
available on the website of the Na-
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The National Agency for Medicines
(NAM) moves to new premises in
Ruskeasuo at Mannerheimintie
103b, on 14 and 15 October 2004.
NAM’s laboratory will remain at its
present address of Mannerheimintie
166, FI-00300 Helsinki. 
The postal address and the tele-
phone numbers to the exchange, to
direct lines and faxes will remain
unchanged. The postal address is PO
Box 55, FI-00301 Helsinki, Finland.
The registry office and incoming
mail reception will be on the 4th
floor. The goods reception will be
past the main entrance on the
ground floor on the Nauvontie side
of the building. 
We apologise for any possible de-
lays in telecommunications during
week 42. In urgent cases it is advis-
able to telephone directly to a mo-
bile phone number or to transmit
faxes to (intl. +358 9) 714 469). 
We hope that visits to NAM dur-
ing and immediately after the move
will be kept to a minimum, and that
application material and other
goods are addressed to our new
premises as of the following weeks. 
During the move, our mobile
phone numbers will be operational.
Pharmacovigilance Department,
( intl .  +358 50) 552 1091 (urgent
pharmacovigilance matters)  
Marketing Authorisation Depart-
ment,  ( intl  +358 50) 511 4031 
Enforcement and Inspection De-
partment,  ( intl  +358 50) 561 2680
(product defects,  medicines’  
manufacturing and distr ibution) 
Laboratory,  ( intl  +358 50) 
302 2709 
Medical  Devices Department,  ( intl
+358 50) 563 8532 (adverse inci-
dents)
Administration Department,  ( intl
+358 50) 520 3126 ( invoices,  
access control,  security)
Hannes Wahlroos, Director General, 
(intl +358 50) 500 3709
Erkki Palva, Head of Safety and Drug In-
formation Department, (intl +358 50)
552 1154
Petri Pommelin, Head of Medical De-
vices Department, (intl +358 50) 563
8531
Juhani Sivula, Head of Administration
Department, (intl +358 50) 552 1124
Olavi Tokola, Head of Marketing Autho-
risation Department, (intl +358 50) 511
4048
Liisa Turakka, Head of Enforcement and
Inspection Department, (intl +358 50)
561 2715
Liisa Kaartinen, (intl +358 50)  565 8104
(Veterinary medicine) 
Seija Ahonen, (intl +358 400) 467 719
(IT matters, telephonic communications) 
Katja Lindgren-Äimänen, (intl +358 50)
511 1657 (Press)
Centre for Pharmacotherapy Devel-
opment  will have offices on the 4th
floor of NAM’s new premises. The
centre’s telephone and fax numbers
will remain unchanged. The visiting
address will be Mannerheimintie
103b, FI-00300 Helsinki, Finland.
The postal address is PO Box 55, FI-
00301 Helsinki, Finland. Manager
Taina Mäntyranta’s mobile phone
number is (intl +358 50) 5812769 
Translation Sari Jay
The Finnish National Agency for Medicines is
moving in week 42 
